• Estradiol-ERα Axis Normalizes T Cell Function via ER Stress

  2026-04-14

  This study reveals that 17β-estradiol restores splenic CD4+ T lymphocyte proliferation and cytokine production following hemorrhagic shock by inhibiting endoplasmic reticulum (ER) stress, primarily through estrogen receptor alpha (ERα) and GPR30. The findings highlight an immunomodulatory mechanism with potential relevance for research into estrogen signaling and immune dysfunction after trauma.

• Gepotidacin in Antibacterial Research: Evidence, Protocols,

  2026-04-13

  Explore Gepotidacin’s unique dual action on bacterial topoisomerases, integrating robust clinical and laboratory evidence. This article offers research-driven guidance for antibacterial applications, setting it apart with critical protocol insights and a deep dive into translational assay decision-making.

• Nonconventional Agonist-Antagonist Interplay at the GLP-1 Re

  2026-04-12

  This study uncovers that glucagon, traditionally considered selective for its own receptor, can act as a nonconventional agonist at the GLP-1 receptor, with its effects modulated by diverse antagonists. High-throughput FRET-based cAMP assays reveal complex cross-reactivity and suggest the need to reevaluate assumptions in GLP-1 and glucagon receptor signaling research.

• γH2AX DNA Damage Detection Kit: Precision DNA Damage Biomark

  2026-04-12

  Empower your DNA damage and repair research with the γH2AX DNA Damage Detection Kit (Mouse mAb/Red) from APExBIO, combining robust specificity with workflow flexibility. This guide translates advanced radiobiology findings into actionable protocols, troubleshooting, and strategic assay enhancements for next-level genomic instability analysis.

• RITA (NSC 652287): Precision Tool for Renal Carcinoma Resear

  2026-04-11

  RITA (NSC 652287) stands out as a selective MDM2-p53 interaction inhibitor, offering robust performance in apoptosis assays and tumor xenograft models. This article translates cutting-edge findings into actionable protocols and troubleshooting strategies for experimental cancer biology.

• TaqI Restriction Endonuclease: Fast, Reliable DNA Digestion

  2026-04-11

  TaqI Restriction Endonuclease enables rapid, precise cleavage of plasmid, PCR, and genomic DNA, supporting streamlined molecular biology workflows where quick and reliable digestion is critical. This product is ideal for research settings requiring rapid turnaround, but is not intended for diagnostic or clinical use.

• Bortezomib (PS-341): Reversible Proteasome Inhibition at ...

  2026-04-10

  This thought-leadership article explores the expanding frontiers of Bortezomib (PS-341) as a reversible proteasome inhibitor for cancer therapy and translational research. We synthesize mechanistic insights—especially the intersection of proteasome inhibition with the mTORC1-CTLH-WDR26 E3-UCK2 axis in pyrimidine metabolism—while offering strategic, evidence-based guidance for researchers. Integrating recent literature and benchmarking best practices, we chart how Bortezomib enables next-generation studies of apoptosis, cancer cell metabolism, and drug development, with actionable recommendations beyond conventional product pages.

• Biotin-16-UTP: Transforming Metatranscriptomics and Envir...

  2026-04-09

  Discover how Biotin-16-UTP, a leading biotin-labeled uridine triphosphate, is revolutionizing biotin-labeled RNA synthesis for metatranscriptomic and aerosol microbiome research. This in-depth analysis explores advanced RNA detection, purification, and real-world applications beyond standard protocols.

• Cy5 TSA Fluorescence System Kit: Signal Amplification for...

  2026-04-08

  The Cy5 TSA Fluorescence System Kit enables robust, enzyme-mediated signal amplification for immunohistochemistry and in situ hybridization, achieving up to 100-fold sensitivity enhancement. This tyramide signal amplification kit supports precise detection of low-abundance targets, reducing primary antibody consumption and increasing reproducibility.

• Bortezomib (PS-341): Reversible 20S Proteasome Inhibitor ...

  2026-04-08

  Bortezomib (PS-341) is a validated reversible proteasome inhibitor with robust activity in cancer models. This article details its chemical properties, mechanism, clinical benchmarks, and research applications, emphasizing its role in apoptosis induction and proteasome-regulated cellular process studies.

• Cy5 TSA Fluorescence System Kit: Pushing the Boundaries o...

  2026-04-07

  Explore how the Cy5 TSA Fluorescence System Kit delivers exceptional signal amplification for ultrasensitive detection in immunohistochemistry, in situ hybridization, and beyond. This article uniquely delves into the molecular mechanism, technical advantages, and its emerging role in detecting inflammatory pathways in cardiovascular research.

• Cy5 TSA Fluorescence System Kit: Signal Amplification for...

  2026-04-07

  The Cy5 Tyramide Signal Amplification (TSA) Fluorescence System Kit delivers up to 100-fold signal amplification for immunohistochemistry and in situ hybridization. This tyramide signal amplification kit enables sensitive, enzyme-mediated Cy5 labeling for low-abundance targets, facilitating high-resolution fluorescence detection.

• Bortezomib (PS-341): Reversible Proteasome Inhibitor Benc...

  2026-04-06

  Bortezomib (PS-341) is a potent, reversible proteasome inhibitor widely validated for cancer research and apoptosis pathway studies. Its high selectivity for the 20S proteasome and robust antiproliferative activity in diverse cell models position it as a benchmark tool in oncology and cell signaling research.

• Bortezomib (PS-341): Applied Proteasome Inhibitor Workflo...

  2026-04-06

  Bortezomib (PS-341) stands as the gold-standard reversible proteasome inhibitor, uniquely empowering apoptosis, proteasome-regulated cellular process, and cancer therapy investigations. Discover streamlined protocols, advanced troubleshooting tips, and comparative insights that maximize experimental reliability in multiple myeloma, mantle cell lymphoma, and melanoma research.

• Bortezomib (PS-341): Reversible 20S Proteasome Inhibitor ...

  2026-04-05

  Bortezomib (PS-341) is a potent, reversible proteasome inhibitor widely used in cancer therapy and apoptosis signaling pathway research. It exhibits nanomolar IC50 values in various cancer cell lines and is clinically approved for relapsed multiple myeloma and mantle cell lymphoma. This article provides atomic, verifiable facts about its mechanism, benchmarks, and optimal use parameters.

16920 records 1/1128 page Next 12345 下5页 Last page